@article{ref1,
title="Safety and risk assessment of no-prescription online semaglutide purchases",
journal="JAMA network open",
year="2024",
author="Ashraf, Amir Reza and Mackey, Tim K. and Schmidt, János and Kulcsár, Győző and Vida, Róbert György and Li, Jiawei and Fittler, András",
volume="7",
number="8",
pages="e2428280-e2428280",
abstract="<p>The popularity of branded semaglutide is surging, with widespread media coverage, viral social media exposure, and celebrity endorsements.1 Although Wegovy (Novo Nordisk) is approved for long-term weight management, Ozempic (Novo Nordisk) (only approved for type 2 diabetes) is often used off-label for this purpose. Global regulatory agencies, including the US Food and Drug Administration (FDA), European Medicines Agency, and World Health Organization (WHO), have warned about fake versions driven by patient demand, high cost, and shortages. Illegal online pharmacies, which operate without valid licenses and sell medicines like semaglutide without prescription, represent a consumer risk for ineffective and dangerous products. ...</p>",
language="en",
issn="2574-3805",
doi="10.1001/jamanetworkopen.2024.28280",
url="http://dx.doi.org/10.1001/jamanetworkopen.2024.28280"
}